The anti-inflammatory pathways modulated by GLP-1 receptor activation (NF-kB suppression, macrophage polarization, Treg enhancement) are largely distinct from the pathways targeted by: Methotrexate: Folate metabolism disruption, different anti-inflammatory pathway TNF inhibitors (adalimumab, etanercept): Direct TNF blockade, whereas GLP-1 reduces TNF production upstream IL-6 inhibitors (tocilizumab): Receptor-level blockade, while GLP-1 reduces IL-6 production JAK inhibitors (tofacitinib, baricitinib): Different signaling pathway entirely Corticosteroids: Broad immunosuppression, while GLP-1 is immunomodulatory This pathway complementarity is why additive benefit is biologically plausible
If you want coaching, nutrition guidance, or community support alongside your medication, then Gimme Care wont be a fit
Sometimes slower
Kritsiligkou P, Chatzi A, Charalampous G, Mironov A Jr, Grant CM, Tokatlidis K
Over time, it can cause irreversible nerve damage, cognitive decline, and mental health disorders such as depression